Effect of Prostaglandin Analogues on Central Corneal Thickness: 3-Year Follow-up Results

Purpose: To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) inpatients with normal tension glaucoma (NTG). Methods: We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who weretreated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy wereincluded. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment. Results: In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1,2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 μm [p = 0.00]; 2 years, 521.67 ± 36.79μm [p = 0.00]; 3 years, 520.43 ± 36.88 μm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005%latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% tafluprostgroup and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisticaldifference was observed between the NTG subgroups (p = 0.06). Conclusions: Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. Along-term follow-up study including more participants is needed.